As antimicrobial resistance (AMR) surges, new antibiotics are scarce. With global leaders set to discuss the crisis, why is the development pipeline so dry and what can be done to address the growing threat?
As the world faces an escalating crisis of antimicrobial resistance (AMR), the need for new antibiotics has never been more urgent. Yet, despite the looming threat of drug-resistant infections, the pipeline for novel treatments remains alarmingly thin. This paradox is set to be a focal point at the upcoming UN General Assembly, where global leaders will grapple with strategies to address AMR and revitalize antibiotic development.
The rise of drug-resistant infections is a stark reminder of how modern medicine’s triumphs are increasingly under threat. The death toll from drug-resistant bacteria reached 1.27 million in 2019, and the economic costs of AMR are projected to surpass $1 trillion by 2030. Sub-Saharan Africa bears a disproportionate burden, particularly among children under five, where drug resistance compounds an already dire public health situation.
The crisis is exacerbated by a troubling stagnation in antibiotic development. Since 1990, only one new class of antibiotics has been discovered, a significant drop from the more than 25 new classes identified between 1940 and 1979. This slowdown is largely due to severe financial constraints and disinterest from major pharmaceutical companies, which have pivoted to more profitable ventures.
One major issue is the financial model for antibiotics. Unlike chronic medications for conditions like diabetes or hypertension, which generate sustained revenue from long-term use, antibiotics are typically used for short durations. This transient use makes it challenging for companies to recoup the substantial costs associated with developing new drugs. As a result, many smaller companies involved in AMR research are struggling financially, with several facing bankruptcy despite their promising breakthroughs.
The landscape of antibiotic research and development is also fraught with difficulties. Of the 112 commercial institutions engaged in preclinical research on AMR, 97 have fewer than 50 employees. This fragility poses a significant risk to the continuity of research efforts and innovation.
To tackle the crisis, experts argue for the need to enhance incentives for both research and market introduction of new antibiotics. In the UK, a subscription model has been introduced, providing drug companies with a fixed annual fee for new antibiotics, regardless of usage. This model aims to ensure that critical drugs remain available while reducing the financial risks for companies.
However, similar approaches are still under consideration in other regions, and there are concerns about their potential impact on global access. Health campaigners fear that such models might drive up the costs of antibiotics worldwide, making it even harder for developing countries to obtain these essential medications.
Addressing the AMR crisis requires a multifaceted approach. Governments and the private sector need to collaborate on funding and incentives that support both early-stage research and the market introduction of new antibiotics. Moreover, efforts must be made to ensure that these innovations are accessible and affordable across all countries and populations.
The UN General Assembly’s discussions on AMR will be crucial in shaping the future of global health policy. As the world grapples with this mounting challenge, a renewed focus on innovation, investment, and equitable access will be essential to preserving the effectiveness of antibiotics and safeguarding public health.
In the face of this critical situation, the call to action is clear: the global community must rally to overcome the barriers to antibiotic development and ensure that life-saving treatments remain within reach for all.
